icon-menu Close
icon-menu
DONATE JOIN
About
Society Public Statements
Access our public statements.

 

June 10, 2025
The Society joined more than 100 organizations in a letter to Congressional leadership urging them to reject proposed NIH funding cuts, make research funds accessible, and exercise rigorous oversight of the agency’s planned restructuring.
May 22, 2025
The Society, ACOG, and more than a dozen partner organizations issued a joint statement reaffirming the safety, efficacy and critical role of mifepristone in reproductive healthcare.
May 2, 2025
The Society submitted a letter to the Food and Drug Administration urging it to reject scientifically unsupported claims and instead uphold the overwhelming evidence demonstrating mifepristone’s safety and efficacy.
April 28, 2025
The Society signed a joint letter alongside more than 500 health and research organizations urging Congress to reject the administration’s proposed FY2026 budget for the Department of Health and Human Services (HHS), which would cut nearly one-third of HHS discretionary funding, gutting the country’s research, scientific, and public health infrastructure.
April 3, 2025
Society statement on mounting attacks on our public health infrastructure
March 26, 2025
The Society joined ACOG in an amicus brief highlighting the 2024 HIPAA Privacy Rule’s role in reducing confusion for healthcare providers and supporting the flow of information for public health.
March 12, 2025
The Society signed on to an amicus brief in Medina v. Planned Parenthood South Atlantic, challenging South Carolina’s attempt to remove Planned Parenthood South Atlantic as a Medicaid provider.
March 10, 2025
The Society joined an amicus brief led by If/When/How: Lawyering for Reproductive Justice highlighting the role of the 2024 HIPAA Privacy Rule in reducing fear of the healthcare system and preventing unnecessary criminal-legal reporting.
February 12, 2025
The Society issued a joint statement with ACOG and other colleague organizations expressing concern over growing threats to the patient-physician relationship, including political interference that undermines medical expertise and patient autonomy.
February 10, 2025
Society statement on advancing our vision, together
January 31, 2025
The Society joined ACOG and SMFM in submitting a citizen petition to the Food and Drug Administration, asking the agency to remove the remaining restrictions imposed on mifepristone under the risk evaluation and mitigation strategy.
January 22, 2025
The Society, alongside ACOG and other colleague organizations, signed a letter urging members of Congress to oppose H.R. 21/S. 6.
December 24, 2024
The Society signed on to Free the Pill’s comment on the Biden Administration’s Proposed Rule for Enhancing Coverage of Preventive Services under the Affordable Care Act.
October 21, 2024
The Society signed on to an amicus brief in Bryant v. Stein, challenging North Carolina’s restrictions on mifepristone.
October 17, 2024
The Society issued a joint public statement led by the American College of Obstetricians and Gynecologists urging the United States Congress and the administration to finalize the Equal Rights Amendment.
August 16, 2024
The Society signed on to an amicus curiae brief in support of Arizona for Abortion Access in Arizona Right to Life v. Fontes.
August 15, 2024
The Society signed on to an amicus brief in Planned Parenthood of Montana v. Montana challenging the state’s twenty-week abortion ban.
August 8, 2024
The Society issued a joint public statement led by the Society for Maternal-Fetal Medicine in the wake of the US Supreme Court decisions regarding EMTALA and mifepristone.
June 27, 2024
The Society released a statement about the Supreme Court (SCOTUS) decision in the EMTALA Case.  
June 18, 2024
The Society joined ACOG and other partners in a statement urging the US Food and Drug Administration to permanently remove the remaining restrictions imposed on mifepristone under the risk evaluation and mitigation strategy (REMS).
June 13, 2024
The Society of Family Planning is relieved by the Supreme Court (SCOTUS) decision in United States Food and Drug Administration (FDA) v Alliance for Hippocratic Medicine. This decision by SCOTUS reflects decades of strong science demonstrating the safety and efficacy of mifepristone. 
April 24, 2024
The Society joined ACOG and other partners in a statement urging the Supreme Court not to weaken Emergency Medical Treatment and Labor Act (EMTALA) protections for patients seeking emergency abortion care, ahead of oral arguments in Idaho v United States.
March 22, 2024
The Society issued a joint public statement, led by the Society for Maternal-Fetal Medicine, urging the Supreme Court to protect access to mifepristone ahead of the Supreme Court oral arguments for AHM v. FDA.
March 1, 2024
The Society released a statement reiterating the evidence-based recommendation against Rh testing in early pregnancy.
January 16, 2024
The Society signed on to an amicus brief in Planned Parenthood of the Heartland v. Iowa challenging their six-week ban.
October 13, 2023
The Society joined several other organizations in submitting an amicus brief to the Supreme Court of the United States in Danco Laboratories, LLC v. Alliance for Hippocratic Medicine, which calls on the Court to stay the US District Court for the Northern District of Texas’s order blocking the Food and Drug Administration’s approval of mifepristone.
September 20, 2023
The Society signed on to a coalition letter prepared by Free the Pill urging the Biden Administration, Departments of Health and Human Services, Labor, and Treasury to issue immediate guidance ensuring that insurance plans must cover all FDA approved over-the-counter birth control, in accordance with the Affordable Care Act.
August 2, 2023
The Society, along with ACOG and SMFM, signed on to a letter to the Colorado Medical Board urging them to follow the science and protect pregnant people by acknowledging “abortion reversal” is not accepted standard medical practice.
July 13, 2023
The Society signed on to an amicus brief in Fund Texas Choice v. Garza challenging restrictions preventing providers from helping patients seek care in other states for impeding constitutionally protected rights to travel and free speech.
June 23, 2023
The Society signed on to ACOG’s Dobbs Anniversary Statement and Call to Action.
June 21, 2023
The Society signed on to an amicus brief in Planned Parenthood South Atlantic v. Phillip, challenging South Carolina’s attempt to exclude Planned Parenthood from its Medicaid program.
June 20, 2023
The Society signed ACOG’s letter to HHS to express appreciation for the proposed HIPAA Privacy Rule to Support Reproductive Health Care Privacy and to share recommendations for how the rule could be improved further.
April 20, 2023
The Society submitted written testimony in support of the over-the-counter oral contraceptive pill application before the FDA.
April 14, 2023
The Society signed on to an amicus brief for the Supreme Court supporting a stay on Judge Kacsmaryk’s decision in Alliance for Hippocratic Medicine v FDA.
April 11, 2023
The Society signed on to an amicus brief for the Fifth Circuit supporting a stay on Judge Kacsmaryk’s decision in Alliance for Hippocratic Medicine v FDA.
April 7, 2023
Society Statement on Alliance for Hippocratic Medicine et al v US Food and Drug Administration Ruling.
March 17, 2023
The Society signed on to a letter from the Free the Pill coalition to the Commissioner of the FDA encouraging him to set a date for the FDA’s advisory committee to discuss an application for an OTC birth control pill submitted seven months ago.
March 6, 2023
The Society, ACOG, and SMFM sent a letter to the FDA urging the FDA to communicate their plans to handle interference with mifepristone’s FDA approval and encouraging them to preserve and enhance access to mifepristone.
February 10, 2023
The Society signed on to an amicus brief filed by ACOG in the case of Alliance for Hippocratic Medicine v FDA uplifting the safety and efficacy of mifepristone and challenging a group of organizations suing the FDA in an effort to dramatically limit access to medication abortion.
October 4, 2022
Nearly 50 of the nation’s leading medical and scientific associations, research institutions, and advocacy organizations urge the FDA to add miscarriage to the label for mifepristone.
September 14, 2022
More than 150 physicians and activists send a letter to Google demanding they take immediate action to prevent anti-abortion advertisements.
August 15, 2022
Over 600 experts urge the media to stop granting airtime to anti-abortion extremists.
July 14, 2022
Adolescent health organizations share a statement condemning the Supreme Court decision in Dobbs v Jackson Women’s Health Organization as a violation of human rights and detrimental to adolescents and young adults.
July 14, 2022
Physicians and activists collaborate on a letter to major social media platforms demanding they take immediate action to address widespread disinformation about abortion.
July 11, 2022
The Free the Pill Coalition celebrates the first-ever application for an OTC birth-control pill in the US
July 7, 2022
More than 75  healthcare organizations condemn legislative interference in the practice of medicine.
June 24, 2022
Ten organizations specializing in maternal health sign on to a joint statement opposing the Supreme Court decision for the Dobbs v Jackson Women’s Health Organization case.
June 8, 2022
Senator Tammy Duckworth submits a resolution opposing the criminalization of the full range of reproductive and sexual healthcare, including abortion, gender-affirming care, and contraceptive care. The resolution also disapproves of the criminalization of pregnancy outcomes.
May 12, 2022
Congresswoman Nikema Williams submits a resolution opposing the criminalization of the full range of sexual and reproductive health care such as abortion, gender-affirming care, and contraceptive care. The resolution also disapproves of the criminalization of pregnancy outcomes.
March 31, 2022
Forty-two reproductive health and justice organizations send a letter to lead the FDA through an application process for an OTC birth control pill.